Sznajd J, Idzior-Waluś B, Zabiński J, Wybrańska I, Korzus G, Iwanejko J
Klinika, Chorób Metabolicznych KDB AM w Krakowie.
Przegl Lek. 1990;47(10):706-10.
The effects of a new fibric acid derivative--beclobrate (Turec, Zyma) on serum lipid and apoprotein concentrations in 63 patients with primary hyperlipoproteinemia were examined. Beclobrate was given in the evening, 100 mg, once daily. After 3 months of beclobrate treatment mean total cholesterol concentration in serum decreased from 9.35 to 7.73 mmol/l (17.3%), mean LDL-cholesterol concentration from 6.32 to 5.38 mmol/l (14.9%), mean HDL-cholesterol concentration increased by 0.21 mmol/l (15.3% of initial value). The greatest decrease was observed in triglyceride concentration--by 50% of the initial value. Apoprotein B concentration decreased by 19.7%, apoprotein A1 and A2 concentration increased by 20.3% and 26.8% respectively. Higher initial values of total cholesterol and triglyceride concentration in serum were associated with greater concentration decrease after beclobrate treatment.
研究了一种新型纤维酸衍生物——氯贝酸酯（Turec，Zyma）对63例原发性高脂蛋白血症患者血清脂质和载脂蛋白浓度的影响。氯贝酸酯于晚上服用，每日1次，每次100毫克。氯贝酸酯治疗3个月后，血清总胆固醇平均浓度从9.35毫摩尔/升降至7.73毫摩尔/升（下降17.3%），低密度脂蛋白胆固醇平均浓度从6.32毫摩尔/升降至5.38毫摩尔/升（下降14.9%），高密度脂蛋白胆固醇平均浓度升高0.21毫摩尔/升（升至初始值的15.3%）。甘油三酯浓度下降幅度最大，降至初始值的50%。载脂蛋白B浓度下降19.7%，载脂蛋白A1和A2浓度分别升高20.3%和26.8%。血清总胆固醇和甘油三酯的初始浓度越高，氯贝酸酯治疗后的浓度下降幅度越大。
